阻塞性睡眠呼吸暂停、GLP-1受体激动剂药物治疗与口腔微生物组：相互竞争的生物学影响及口腔健康监测的意义

文献信息

中文摘要

目的： 阻塞性睡眠呼吸暂停（OSA）与可重复出现的口腔微生物组失调相关，其由五条同时存在的生物学通路介导：慢性间歇性缺氧驱动的免疫失调、强制性口呼吸导致唾液干燥、唾液葡萄糖升高促进致龋生物膜增殖、胃食管反流酸挑战，以及下丘脑-垂体-肾上腺轴激活抑制黏膜免疫。2024年12月FDA批准替尔泊肽用于中重度OSA，以及瑞他鲁肽和奥格列隆的出现，使GLP-1受体激动剂（GLP-1RA）处于OSA药物治疗的核心。本综述探讨GLP-1RA治疗在OSA患者中造成的口腔微生物组后果，描述这些药物引入的相互竞争的生物学影响，并确定由此产生的不确定性所带来的监测和研究意义。
方法： 对已发表文献进行叙述性综述，考察OSA相关口腔微生物组失调、与口腔生物学相关的GLP-1RA药理学机制、唾液腺药物警戒数据以及肠道微生物组恢复证据。来源包括检索至2026年6月的PubMed、Web of Science和Scopus数据库。
结果： GLP-1RA治疗涉及五条恢复通路，从机制上对抗每一条OSA驱动的失调机制：直接降低AHI，减轻缺氧驱动的免疫失调；改善咽部气道，减少强制性口呼吸；血糖正常化，减少唾液可发酵底物；延迟胃排空和减轻体重，减轻GERD酸挑战；以及恢复睡眠结构，减少皮质醇介导的黏膜免疫抑制。然而，药物警戒数据表明，司美格鲁肽可能通过β-抑制蛋白介导的受体脱敏损害唾液腺反应性——这是一种相互竞争的口腔风险，可部分或完全抵消恢复获益。替尔泊肽的偏向性激动特征（优先激活cAMP信号而非β-抑制蛋白内化）可能带来差异化的唾液腺安全性，而奥格列隆的每日口服给药引入直接的口咽药物暴露，其微生物学后果尚未被表征。任何接受治疗的患者中口腔微生物组的净结局是这些相互竞争影响的乘积，尚未被前瞻性表征。
结论： OSA中的GLP-1RA药物治疗创造了一个生物学上复杂的口腔微生物组环境，其临床轨迹无法根据当前证据预测。有必要开展前瞻性研究，从治疗开始即进行口腔健康监测在科学上是合理的，并且在睡眠医学、内分泌学和口腔生物学的交汇处确定了七个优先研究问题。

英文摘要

PURPOSE: Obstructive sleep apnea (OSA) is associated with reproducible oral microbiome dysbiosis mediated by five simultaneous biological pathways: chronic intermittent hypoxia-driven immune dysregulation, obligate mouth breathing causing salivary desiccation, elevated salivary glucose promoting cariogenic biofilm proliferation, gastroesophageal reflux acid challenge, and hypothalamic-pituitary-adrenal axis activation suppressing mucosal immunity. The December 2024 FDA approval of tirzepatide for moderate-to-severe OSA and the emergence of retatrutide and orforglipron have placed GLP-1 receptor agonists (GLP-1RAs) at the center of OSA pharmacotherapy. This review examines the oral microbiome consequences of GLP-1RA therapy in OSA patients, characterizes the competing biological influences these agents introduce, and identifies the monitoring and research implications of the resulting uncertainty.
METHODS: A narrative review of published literature examining OSA-related oral microbiome dysbiosis, GLP-1RA pharmacological mechanisms relevant to oral biology, salivary gland pharmacovigilance data, and gut microbiome restoration evidence. Sources included PubMed, Web of Science, and Scopus databases searched through June 2026.
RESULTS: GLP-1RA therapy engages five restoration pathways that mechanistically counter each OSA-driven dysbiosis mechanism: direct AHI reduction, attenuating hypoxia-driven immune dysregulation; pharyngeal airway improvement, reducing obligate mouth breathing; glycemic normalization, reducing salivary fermentable substrate; gastric emptying delay and weight loss, attenuating GERD acid challenge; and sleep architecture restoration, reducing cortisol-mediated mucosal immune suppression. Pharmacovigilance data, however, indicate that semaglutide may impair salivary gland responsiveness through β-arrestin-mediated receptor desensitization-a competing oral risk that partially or fully counteracts the restoration benefits. Tirzepatide's biased agonism profile (preferential activation of cAMP signaling over β-arrestin internalization) may confer differential salivary gland safety, and orforglipron's daily oral dosing introduces direct oropharyngeal drug exposure with uncharacterized microbiological consequences. The net oral microbiome outcome in any treated patient is the product of these competing influences and has not been characterized prospectively.
CONCLUSIONS: GLP-1RA pharmacotherapy in OSA creates a biologically complex oral microbiome environment whose clinical trajectory cannot be predicted from current evidence. Prospective studies are warranted, oral health monitoring beginning at treatment initiation is scientifically justified, and seven priority research questions are identified at the convergence of sleep medicine, endocrinology, and oral biology.